大分割前列腺切除术后放疗13年随访的严重晚期毒性(3-5级)
BACKGROUND: We previously reported outcomes after hypofractionated postprostatectomy radiotherapy (HYPORT) with a median follow-up of 32 months.…
要点
- 15年时晚期3-5级毒性风险为34%,总体生存70%,无生化复发生存52%。
核心结论
- 剂量递增的大分割前列腺切除术后放疗后需要长期随访才能充分捕捉严重毒性。
- 在具有长期生存潜力的该患者人群中广泛采用类似方案前应考虑这一长期毒性风险。
研究设计与样本
- 单中心连续161例前列腺切除术后生化复发患者,2003年至2013年接受图像引导调强放疗的大分割术后放疗(HYPORT)。
- 多数患者(154/161)接受65 Gy分26次照射。
- 中位随访13.5年。
主要发现
- 更高级别毒性包括6例膀胱切除术和3例死亡。
- 2年时仅2例发生晚期3-5级毒性;15年时总体生存70%,无生化复发生存52%,晚期3-5级毒性风险34%。
临床怎么用
- 对接受剂量递增大分割前列腺切除术后放疗的患者需长期随访以充分评估严重晚期毒性。
- 在广泛采用类似方案前应考虑该人群的长期严重毒性风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously reported outcomes after hypofractionated postprostatectomy radiotherapy (HYPORT) with a median follow-up of 32 months. This was a primary citation supporting the fractionation selection for NRG-GU003, which showed noninferiority of HYPORT versus conventional radiotherapy. METHODS: One hundred sixty-one consecutive patients with biochemically recurrent prostate cancer after prostatectomy underwent HYPORT from 2003 to 2013 at a single academic institution using image guided intensity modulated radiation therapy, with the majority (154 of 161) receiving 65 Gy in 26 fractions. RESULTS: Median follow-up was 13.5 years. Forty-four patients (27.3%) experienced 58 late grade 3 to 5 toxicities (LTOX3) a median of 106 months after HYPORT. Fifty-five of 58 LTOX3 were genitourinary related. Higher-grade toxicities included 6 cystectomies and 3 deaths. At 2 years, only 2 patients had experienced an LTOX3. At 15 years, overall survival was 70%, freedom from biochemical recurrence was 52%, and the risk of LTOX3 was 34%. CONCLUSIONS: Long follow-up is needed to fully capture severe toxicities after dose-escalated HYPORT. This should be considered prior to the broad adoption of similar regimens for this patient population with long survival potential.
引用
- Ranta K, Wojcieszynski AP, Zhao SG, et al. Severe Late Toxicities (Grade 3-5) With 13 Years of Follow-up after Hypofractionated Postprostatectomy Radiotherapy. Int J Radiat Oncol Biol Phys. 2025. PMID: 40222393. doi:10.1016/j.ijrobp.2025.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。